title: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).
abstract: BACKGROUND
  Surgery for advanced esophageal carcinoma has its limits as regards aggressiveness and therapeutic effect, therefore effective multimodality treatment is required to obtain better survival. The objective of this study was to evaluate whether daily continuous infusion of CDDP could achieve a higher clinical response rate with less toxicity than its drip infusion in the previous phase II study that we had conducted.
  
  
  METHODS
  Patients with primary extensive or relapsed esophageal carcinoma after esophagectomy, which had distant organ metastasis and histologically proven SCC, were eligible for this study. A dose of 20 mg/m(2) of cisplatin and 800 mg/m(2) of 5-fluorouracil was given by continuous infusion for 24 h on days 1-5. This treatment was repeated every 4 weeks for up to four cycles. A total of 36 men and six women with a median age of 64 (range 39-75) years were registered and 36 patients were eligible.
  
  
  RESULTS
  The overall response rate of the registered patients was 33.3% (12/36) and the median response duration was 175 days. Median survival time was 201.5 days and the 1-year survival rate was 27.8%. Change from bolus to continuous infusion of cisplatin affected neither the type nor the degree of toxicity.
  
  
  CONCLUSIONS
  Daily continuous infusion of cisplatin was not associated with higher response or lower toxicity than those seen with the high-dose bolus or multibolus treatment regimens. We conclude that this regimen in this setting is not worthy of further phase III trials. JEOG is now evaluating other drug combination regimens.
authors.affiliation: Department of Surgery, Institute of Gastroenterology,Tokyo Women's Medical University, Tokyo, Japan. hayashi@hosp.net
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: N
authors.initials: N
authors.lastname: Ando
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Ide
authors.forename: K
authors.initials: K
authors.lastname: Nagai
authors.forename: N
authors.initials: N
authors.lastname: Aoyama
authors.forename: W
authors.initials: W
authors.lastname: Takiyama
authors.forename: K
authors.initials: K
authors.lastname: Ishida
authors.forename: K
authors.initials: K
authors.lastname: Isono
authors.forename: H
authors.initials: H
authors.lastname: Makuuchi
authors.forename: M
authors.initials: M
authors.lastname: Imamura
authors.forename: M
authors.initials: M
authors.lastname: Shinoda
authors.forename: S
authors.initials: S
authors.lastname: Ikeuchi
authors.forename: T
authors.initials: T
authors.lastname: Kabuto
authors.forename: H
authors.initials: H
authors.lastname: Yamana
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil